Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects With CF, Homozygous for the F508del-CFTR Mutation [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluated the efficacy and safety of lumacaftor in combination with ivacaftor in cystic fibrosis patients homozygous for the F508del-CFTR mutati…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• ORKAMBI (lumacaftor and ivacaftor)

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Cystic Fibrosis | Phase 3 | Status: COMPLETED | Results posted: 2017-10-23